Data highlights progress in developing bioprinted tissue therapeutics to treat acquired and congenital liver diseases
Vancouver, BC, Canada – October 26, 2023 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced the presentation of new preclinical data on its bioprinted liver tissue platform at the The Liver Meeting® 2023, hosted by the American Association for the Study of Liver Diseases (AASLD), held in Boston, MA from November 10-14, 2023. The three poster presentations will highlight the advancement of Aspect’s bioprinted liver tissue platform for the treatment of acute liver failure and chronic congenital liver diseases.
“Our platform approach for creating hepatic bioprinted tissue therapeutics holds immense potential to treat multiple acquired and congenital liver diseases,” said Tamer Mohamed, Founder and CEO, Aspect Biosystems. “Our latest data represents an encouraging step on our path towards first-in-human studies for an off-the-shelf bioengineered liver tissue that we believe would have a profound impact on the lives of people suffering from serious liver conditions.”
Poster Presentation Details:
Title: Hepatic Bioprinted Tissue Therapeutics (BTTs) as a cell therapy for monogenic liver diseases including PKU and A1AT deficiency
- Poster #: 3316-A
- Date: Sunday, November 12, 2023
- Time: 1:00-2:00pm
Title: Hepatic Bioprinted Tissue Therapeutics (BTTs) demonstrate comparable function when implanted into intraperitoneal or subcutaneous sites
- Poster #: 4313-A
- Date: Monday, November 13, 2023
- Time: 1:00-2:00pm
Title: Hepatic Bioprinted Tissue Therapeutics (BTTs) rescue mice from CCl4-induced acute liver failure
- Poster #: 4314-A
- Date: Monday, November 13, 2023
- Time: 1:00-2:00pm
About The Liver Meeting®
Hosted by the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, and congenital liver disorders. Learn more at www.aspectbiosystems.com.
Contact
Emily Stearney
HDMZ
Aspect.PR@HDMZ.com